NEW YORK, July 14, 2026 /PRNewswire/ -- Loews Corporation (NYSE: L) will report second quarter 2026 financial results on Monday, August 3, 2026.
On that date the Company will also post earnings remarks on its website. These remarks will include commentary from the Company's Chief Executive Officer, Ben Tisch, and Chief Financial Officer, Jane Wang.
The news release and earnings remarks will be available online at the Loews Corporation website (www.loews.com).
About Loews Corporation
Loews Corporation is a diversified company with businesses in the insurance, energy, hospitality, and packaging industries. For more information, please visit www.loews.com.
As EQB prepares to close its Acquisition of PC Financial on July 1, 2026, the company announces a strengthened leadership team drawing on talent from both organizations, positioning EQB for a differentiated phase of growth Key appointments include: Ian Hanning from PC Financial to SVP, Credit Cards and Loyalty Mark Snyder from PC Financial to SVP, Credit Risk and Data Analytics Michaela Garfield from PC Financial to SVP, Customer Growth, Experience and Strategy, Personal Banking Puneesh Arora from PC Financial to EVP and Chief Risk Officer, with current EVP and Chief Risk Officer Marlene Lenarduzzi to act as Special Advisor until Jan 1, 2027 Daniel Rethazy's mandate expanding as EVP Personal Banking to include PC Financial businesses Anilisa Sainani's mandate as CFO expanding to include Strategy and Corporate Development Gavin Stanley's mandate as CHRO expanding to include Brand and Marketing Caleb Rubin appointed as Chief Brand Officer Dan Broten appointed Chief Digital Officer David Wilkes appointed SVP, Deposits, Payments and Small Business Banking Dipti Patel elevated to Chief Credit Officer and Deputy CRO Julia Davidson appointed Chief Operating Officer, Commercial Banking Lemar Persaud appointed SVP, Investor Relations and Enterprise Performance Management TORONTO, June 16, 2026 /PRNewswire/ - EQB Inc. (TSX: EQB) today announced a comprehensive set of executive appointments and elevations as the company prepares to close its acquisition ("the Acquisition") of PC Financial1 from Loblaw Companies Limited ("Loblaw") (TSX: L) on July 1, 2026. This strengthened leadership team brings multiple senior PC Financial leaders onto the EQB Executive Leadership Team (ELT), alongside a series of expanded mandates for existing leaders, building the organizational capabilities required to serve millions of Canadians across a broader and more complex set of financial products and services.
NEW YORK, April 14, 2026 /PRNewswire/ -- Loews Corporation (NYSE: L) will report first quarter 2026 financial results on Monday, May 4, 2026.
On that date the Company will also post earnings remarks on its website. These remarks will include commentary from the Company's Chief Executive Officer, Ben Tisch, and Chief Financial Officer, Jane Wang.
The news release and earnings remarks will be available online at the Loews Corporation website (www.loews.com).
About Loews Corporation
Loews Corporation is a diversified company with businesses in the insurance, energy, hospitality and packaging industries. For more information, please visit www.loews.com.
TORONTO, April 28, 2026 (GLOBE NEWSWIRE) -- Loblaw has issued its March Food Inflation Report, with context around what’s impacting food prices and what it expects in the future.
Based on the latest StatsCan data, inflation climbed to 2.4% year over year in March, following a 1.8% increase the month prior. StatsCan attributes roughly 20 basis points of the March result to the ongoing crisis in the Middle East. The price of food purchased from stores rose in March as well, to 4.4%, with the price of fresh vegetables (+7.8%) seeing its largest increase in over two and a half years. Tighter supply and weather contributed to this result.
April 28, 2026 15:40 ET | Source: Loblaw Companies Limited
BRAMPTON, Ontario, April 28, 2026 (GLOBE NEWSWIRE) -- Out of an abundance of caution, Loblaw Companies Limited is recalling select cases of PC® Cola (12 x 355 ML) products with UPC 060383787035.
Inside some of the cases, cans labelled as PC® Cola Zero Sugar may contain regular PC® Cola. This may be a health concern for customers who are avoiding sugar.
Only products with the 2026NO20 PQ XXXX lot code are affected by the recall. The affected products were sold between April 2, 2026 and April 27, 2026 at the following stores:
Ontario: Real Canadian Superstore, Fortinos, Loblaws, Valu-Mart, Your Independent Grocer, Zehrs, No Frills, affiliated independent stores, Wholesale Club, no name store, Shoppers Drug Mart
Atlantic: Atlantic Superstore, Dominion, Your Independent Grocer, Maxi, No Frills, affiliated independent stores, Shoppers Drug Mart
Québec: Provigo, Maxi, Axep, Intermarché, Valu-Mart, Club Entrepôt, Pharmaprix
West: Real Canadian Superstore, Independent franchise stores, Your Independent Grocer, Extra Foods, No Frills, independent retail stores, Real Canadian Wholesale Club, Wholesale Club, Shoppers Drug Mart
All affected products have been removed from store shelves. Customers are encouraged to return the product to the place of purchase for a full refund.
We apologize for any inconvenience this may cause. The safety and trust of our customers remain our top priority.
For more information, customers can contact Customer Service at 1-888-495-5111 or visit: http://www.presidentschoice.ca/en_CA/customer-service-feedback-form.html
TORONTO, April 29, 2026 (GLOBE NEWSWIRE) -- It’s time to put your best foot forward for a cause that matters. Registration for the 2026 Shoppers Drug Mart® Run for Women is now open, and Canadians are invited to join a powerful movement.
As Canada’s largest run/walk series dedicated to women’s mental health, the Shoppers Drug Mart® Run for Women has raised over $27 million since 2013. Every dollar raised by participants and supporters directly fuels programs in their own communities, providing everything from crisis counselling and peer support groups to vital research and initiatives that reduce stigma.
Here’s how you can get involved
Whether you are walking or running, everyone can join the fun! Choose between a 5km or 10km route and participate solo or build a team with friends, family, or coworkers. Participants are encouraged to fundraise and those raising $150 or more can earn exciting rewards like PC Optimum™ points or Running Room gift cards.
Learn about the impact you’re having
The money raised across the 18 events funds local mental health charities and programs that expand access to care and support for women across Canada.
“The Shoppers Drug Mart® Run for Women is more than a national event, it’s a movement” shares Carrie Trembinski, Vice President, Communications and Community Engagement at St. Joseph’s Healthcare Foundation. “Together, we’re forging a path towards greater understanding, equity, and access to care for women experiencing mental health concerns. The Run celebrates the strength of women while building a community that makes women feel safe in asking for help when they need it. And that is powerful.”
Find your community, be part of the movement
Registration is now open for events taking place in 18 cities across Canada:
Moncton, NB (May 3, 2026)Vancouver, BC (May 9, 2026)Waterloo, ON (May 9, 2026)Edmonton, AB (May 23, 2026)Oakville, ON (May 23, 2026)Markham, ON (May 24, 2026)Montreal, QC (May 30, 2026)Victoria, BC (May 30, 2026)Ottawa, ON (May 31, 2026)Toronto, ON (June 6, 2026)Winnipeg, MB (June 6, 2026)Hamilton, ON (June 7, 2026)London, ON (June 13, 2026)Quebec City, QC (June 13, 2026)Saskatoon, SK (June 13, 2026)St. John’s, NL (June 13, 2026)Calgary, AB (June 20, 2026)Whitby, ON (June 20, 2026)
Whether you join an event or choose to donate, your support helps create a future where every woman in Canada can access the mental health care she deserves.
To sign up for an event in your community or to donate today, visit runforwomen.ca.
About Shoppers Foundation for Women’s HealthTM
Shoppers Foundation for Women’s HealthTM – the charitable arm of Shoppers Drug Mart® – is committed to helping Canadian women lead healthier lives, by making care more equitable and accessible. In 2022, the Foundation set an ambitious goal: to contribute $50M by 2026 towards women’s health initiatives that are making care more equitable and accessible. This milestone has been surpassed, ahead of schedule, and Shoppers Foundation remains steadfast in its commitment to build a future in which more women in Canada can lead healthier lives." Learn more at shoppersfoundation.ca.
About Shoppers Drug Mart Inc.
Shoppers Drug Mart Inc. is one of the most recognized and trusted names in Canadian retailing. The company is the licensor of full-service retail drug stores operating under the name Shoppers Drug Mart® (Pharmaprix® in Québec). With more than 1,350 Shoppers Drug Mart® and Pharmaprix® stores operating in prime locations in each province and two territories, the company is one of the most convenient retailers in Canada. The company also licenses or owns more than 150 medical clinic pharmacies operating under the name Shoppers Simply Pharmacy® (Pharmaprix Simplement Santé® in Québec). In addition to its retail store network, the company owns Shoppers Drug Mart Specialty Health Network Inc., a provider of specialty drug distribution, pharmacy and comprehensive patient support services, MediSystem Inc., a provider of pharmaceutical products and services to long-term care facilities and Lifemark Health Group, Canada’s leading provider of outpatient physiotherapy, massage therapy, occupational therapy, chiropractic, mental health, and other ancillary rehabilitation services. Shoppers Drug Mart® is an independent operating division of Loblaw Companies Limited.
BRAMPTON, Ontario, April 30, 2026 (GLOBE NEWSWIRE) -- Prepare to satisfy every craving and comfort every emotion! Loblaws®, Zehrs®, and Your Independent Grocer® are thrilled to unveil their new multi-channel “FOODS FOR ALL THE MOODS" brand platform this spring. This platform and campaign are a rich and vibrant celebration of life's moments, big and small, demonstrating how our trusted stores and colleagues consistently provide the perfect food solutions for every mood and occasion. Joining this exciting journey is the beloved culinary expert and television personality, Antoni Porowski, making a fun and engaging return.
“We know that food plays a spectrum of different roles in people’s lives. It has the incredible power to impact, address and change emotions,” says Shelley Tangney, VP of Marketing for the Super Market division at Loblaw Companies Ltd. “Every day, our customers pair what they eat with what they are feeling. Our new “FOODS FOR ALL THE MOODS” content reflects that daily ritual in relatable and playful ways that invites everyone to engage.”
The campaign begins with Antoni assisting customers in relatable scenarios. The spot features him rescuing an overwhelmed dad who is juggling both a stroller and a work call, by arriving with PC Express bags and jokingly proclaiming, "We also deliver!", highlighting the ease and accessibility of grocery delivery services.
The campaign with Antoni will continue into summer, supporting fans through the extreme highs and lows of a soccer match. He appears with two fresh baked cakes, one that says "GOALLL," and one that says "NOOOO", showcasing that stores are ready to cover all game-time emotions from celebration to commiseration.
“People naturally reach for foods that match how they feel, and Antoni is the perfect ‘food-mood matchmaker,’ helping show Canadians how easy it is to find the right food for every mood or moment,” says Bryan Collins, Founder & CCO, ONE23WEST.
The "FOODS FOR ALL THE MOODS" campaign will roll out across television, digital, social media, and in-store channels starting this spring.
About Loblaw Companies Limited
Loblaw is Canada’s food and pharmacy leader, and the nation’s largest retailer. Loblaw provides Canadians with grocery, pharmacy, and healthcare services, other health and beauty products, apparel, general merchandise, financial services and wireless mobile products and services. With more than 2,800 locations, Loblaw, its franchisees and Associate-owners employ more than 220,000 full- and part-time employees, making it one of Canada’s largest private sector employers.
Loblaw’s purpose – Live Life Well® – puts first the needs and well-being of Canadians who make one billion transactions annually in the company’s stores. Loblaw is positioned to meet and exceed those needs in many ways: convenient locations; more than 1,100 grocery stores that span the value spectrum from discount to specialty; full-service pharmacies at nearly 1,400 Shoppers Drug Mart® and Pharmaprix® locations and in close to 500 grocery stores; PC Financial® services; Joe Fresh® fashion and family apparel; and four of Canada’s top-consumer brands in Life Brand®, Farmer’s Market™, no name® and President's Choice®. For more information, visit Loblaw’s website at www.loblaw.ca and Loblaw's issuer profile at www.sedarplus.ca
Photos accompanying this announcement are available at:
, /PRNewswire/ -- Loews Corporation (NYSE: L) today released its first quarter 2026 financial results.
First Quarter 2026 highlights:
Loews Corporation reported net income of $337 million, or $1.63 per share, in the first quarter of 2026, compared to $370 million, or $1.74 per share, in the first quarter of 2025. The following are key highlights of our first quarter results:
CNA Financial Corporation's (NYSE: CNA) net income attributable to Loews Corporation decreased year-over-year primarily due to lower underlying underwriting results and unfavorable net prior year loss reserve development, partially offset by higher net investment income. Boardwalk Pipelines' net income increased year-over-year primarily due to higher contracting rates and utilization-based revenues on gas transportation, as well as higher rates on storage, parking and lending. Loews Hotels' net income increased year-over-year primarily due to higher equity income from joint ventures, driven mainly by the Universal Orlando Resort joint ventures. Corporate segment results decreased year-over-year primarily due to lower investment income from the parent company trading portfolio and higher interest expense. Book value per share increased to $90.90 as of March 31, 2026, from $90.71 as of December 31, 2025. Book value per share, excluding AOCI, increased to $97.20 as of March 31, 2026, from $95.89 as of December 31, 2025. On March 31, 2026, the parent company had $4.5 billion of cash and investments and $1.8 billion of debt. Loews Corporation repurchased 0.3 million shares of its common stock during the first quarter of 2026 for a total cost of $31 million. Consolidated highlights:
Three Months Ended March 31,
(In millions)
2026
2025
Net Income (Loss) Attributable to Loews Corporation:
CNA Financial
$ 194
$ 252
Boardwalk Pipelines
159
152
Loews Hotels & Co
26
—
Corporate
(42)
(34)
Net income attributable to Loews Corporation
$ 337
$ 370
Net income per share attributable to Loews Corporation
$ 1.63
$ 1.74
March 31, 2026
December 31, 2025
Book value per share
$ 90.90
$ 90.71
Book value per share excluding AOCI
$ 97.20
$ 95.89
Shares of common stock outstanding (in millions)
205.8
206.0
Three months ended March 31, 2026 compared to 2025
CNA:
Net income attributable to Loews Corporation was $194 million compared to $252 million. Core income decreased to $225 million compared to $281 million, driven by lower underlying underwriting results and unfavorable net prior year loss reserve development, partially offset by higher net investment income. Net earned premiums grew by 3% and net written premiums grew by 1%. Property and Casualty's combined ratio increased by 3.8 points to 102.2% compared to 98.4% largely due to a higher underlying loss ratio and unfavorable net prior year loss reserve development. Property and Casualty's underlying combined ratio increased to 94.5% from 92.1%. Property and Casualty's underlying loss ratio increased by 2.6 points, mainly driven by higher loss cost trends and lower than expected rate in certain lines in recent quarters. Property and Casualty's unfavorable net prior year loss reserve development increased from $61 million to $100 million mainly driven by professional errors & omissions and excess casualty in recent accident years. Net investment income increased due to higher income from fixed income securities, as a result of a larger invested asset base and favorable reinvestment rates, partially offset by lower common stock returns. Boardwalk:
Net income increased to $159 million compared to $152 million. EBITDA increased to $360 million compared to $346 million. Net income and EBITDA improved due to higher contracting rates and utilization-based revenues on gas transportation as well as higher rates on storage, parking and lending, partially offset by lower product sales and higher operating expenses. Loews Hotels:
Net income increased to $26 million compared to less than $1 million. Adjusted EBITDA increased 53% to $124 million compared to $81 million. Net income and adjusted EBITDA improved primarily due to higher equity income from joint ventures driven by growth in the overall average daily rate and an increase in both the number of available and the number of occupied room nights at the Universal Orlando Resort, including the addition of the three new hotels that opened in 2025. Corporate:
Net loss of $42 million compared to a net loss of $34 million. Results decreased primarily due to lower investment income from the parent company trading portfolio and higher interest expense related to recent debt refinancing. Share Purchases:
On March 31, 2026, there were 205.8 million shares of Loews common stock outstanding. During the three months ended March 31, 2026, Loews Corporation repurchased 0.3 million shares of its common stock for a total cost of $31 million. Depending on market conditions, Loews may from time to time purchase shares of its and its subsidiaries' outstanding common stock in the open market (including, with respect to Loews common stock, in open market transactions that may or may not satisfy all of the conditions of the Rule 10b-18 voluntary safe harbor), in privately negotiated transactions or otherwise. Reconciliation of GAAP Measures to Non-GAAP Measures
This news release contains financial measures that are not in accordance with accounting principles generally accepted in the United States of America ("GAAP"). Management believes some investors may find these measures useful to evaluate our and our subsidiaries' financial performance. CNA utilizes core income, underlying loss ratio and underlying combined ratio. Boardwalk utilizes earnings before interest, income tax expense, depreciation and amortization ("EBITDA"), and Loews Hotels utilizes Adjusted EBITDA. These non-GAAP measures are defined and reconciled to the most comparable GAAP measures on pages 6 and 7 of this release.
Earnings Remarks
For Loews Corporation
Today, May 4, 2026, earnings remarks will be available on the Investors section of our website at www.loews.com. Remarks will include commentary from Loews's president and chief executive officer and chief financial officer. For CNA
Today, May 4, 2026, earnings remarks will be available on the Investor Relations section of CNA's website at www.cna.com. Remarks will include commentary from CNA's president and chief executive officer and chief financial officer. About Loews Corporation
Loews Corporation is a diversified company with businesses in the insurance, energy, hospitality and packaging industries. For more information, please visit www.loews.com.
Forward-Looking Statements
Statements contained in this news release which are not historical facts are "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements are inherently uncertain and subject to a variety of risks that could cause actual results to differ materially from those expected by the Company. A discussion of the important risk factors and other considerations that could materially impact these matters, as well as the Company's overall business and financial performance, can be found in the Company's reports filed with the Securities and Exchange Commission and readers of this release are urged to review those reports carefully when considering these forward-looking statements. Copies of these reports are available through the Company's website (www.loews.com). Given these risk factors, investors and analysts should not place undue reliance on forward-looking statements. Any such forward-looking statements speak only as of the date of this news release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any forward-looking statement is based.
Loews Corporation and Subsidiaries
Selected Financial Information
Three Months Ended March 31,
(In millions)
2026
2025
Revenues:
CNA Financial (a)
$ 3,677
$ 3,627
Boardwalk Pipelines
631
622
Loews Hotels & Co
254
245
Corporate investment income (loss), net and other
(7)
—
Total
$ 4,555
$ 4,494
Income (Loss) Before Income Tax:
CNA Financial (a)
$ 267
$ 349
Boardwalk Pipelines
211
202
Loews Hotels & Co
37
4
Corporate:
Investment income (loss), net
(4)
—
Other (b)
(48)
(41)
Total
$ 463
$ 514
Net Income (Loss) Attributable to Loews Corporation:
CNA Financial (a)
$ 194
$ 252
Boardwalk Pipelines
159
152
Loews Hotels & Co
26
—
Corporate:
Investment income (loss), net
(3)
—
Other (b)
(39)
(34)
Net income attributable to Loews Corporation
$ 337
$ 370
(a)
The three months ended March 31, 2026 and 2025 include net investment losses of $18 million and $9 million ($13 million and $6 million after tax and noncontrolling interests).
(b)
Consists of parent company interest expense, corporate expenses and the equity income (loss) of Altium Packaging.
Loews Corporation and Subsidiaries
Consolidated Financial Review
Three Months Ended March 31,
(In millions, except per share data)
2026
2025
Revenues:
Insurance premiums
$ 2,699
$ 2,626
Net investment income
613
608
Investment losses
(18)
(9)
Operating revenues and other
1,261
1,269
Total
4,555
4,494
Expenses:
Insurance claims and policyholders' benefits
2,175
2,027
Operating expenses and other
1,917
1,953
Total
4,092
3,980
Income before income tax
463
514
Income tax expense
(109)
(122)
Net income
354
392
Amounts attributable to noncontrolling interests
(17)
(22)
Net income attributable to Loews Corporation
$ 337
$ 370
Net income per share attributable to Loews Corporation
$ 1.63
$ 1.74
Weighted average number of shares
206.27
212.60
Definitions of Non-GAAP Measures and Reconciliation of GAAP Measures to Non-GAAP Measures:
CNA Financial Corporation
Core income is calculated by excluding from CNA's net income attributable to Loews Corporation the after-tax effects of investment gains or losses and gains or losses resulting from pension settlement transactions. In addition, core income excludes the effects of noncontrolling interests. The calculation of core income excludes investment gains or losses because they are generally driven by economic factors that are not necessarily reflective of CNA's primary insurance operations. The calculation of core income excludes gains or losses resulting from pension settlement transactions as they result from decisions regarding CNA's defined benefit pension plans which are unrelated to its primary insurance operations.
The following table presents a reconciliation of CNA net income attributable to Loews Corporation to core income:
Three Months Ended March 31,
(In millions)
2026
2025
CNA net income attributable to Loews Corporation
$ 194
$ 252
Investment losses
14
7
Noncontrolling interests
17
22
Core income
$ 225
$ 281
In evaluating the results of Property & Casualty operations, CNA utilizes the loss ratio, the underlying loss ratio, the expense ratio, the dividend ratio, the combined ratio and the underlying combined ratio. These ratios are calculated using GAAP financial results. The loss ratio is the percentage of net incurred claim and claim adjustment expenses to net earned premiums. The underlying loss ratio excludes the impact of catastrophe-related reinstatement premiums, catastrophe losses and development-related items from the loss ratio. Development-related items represent net prior year loss reserve and premium development, and includes the effects of interest accretion and change in allowance for uncollectible reinsurance. The expense ratio is the percentage of insurance underwriting and acquisition expenses, including the amortization of deferred acquisition costs, to net earned premiums. The dividend ratio is the ratio of policyholders' dividends incurred to net earned premiums. The combined ratio is the sum of the loss ratio, the expense ratio and the dividend ratio. The underlying combined ratio is the sum of the underlying loss ratio, the expense ratio and the dividend ratio. The underlying loss ratio and the underlying combined ratio are deemed to be non-GAAP financial measures, and management believes some investors may find these ratios useful to evaluate CNA's underwriting performance since they remove the impact of catastrophe losses which are unpredictable as to timing and amount, and development-related items as they are not indicative of current year underwriting performance.
The following table presents a reconciliation of CNA's loss ratio to underlying loss ratio and CNA's combined ratio to underlying combined ratio:
Three Months Ended March 31,
2026
2025
Loss ratio
71.8 %
67.8 %
Expense ratio
29.9
30.2
Dividend ratio
0.5
0.4
Combined ratio
102.2 %
98.4 %
Less: Effect of catastrophe impacts
3.6
3.8
Less: Effect of development-related items
4.1
2.5
Underlying combined ratio
94.5 %
92.1 %
Underlying loss ratio
64.1 %
61.5 %
Boardwalk Pipelines
EBITDA is defined as earnings before interest, income tax expense, depreciation and amortization. The following table presents a reconciliation of Boardwalk's net income attributable to Loews Corporation to its EBITDA:
Three Months Ended March 31,
(In millions)
2026
2025
Boardwalk net income attributable to Loews Corporation
$ 159
$ 152
Interest, net
38
38
Income tax expense
52
50
Depreciation and amortization
111
106
EBITDA
$ 360
$ 346
Loews Hotels & Co
Adjusted EBITDA is calculated by excluding from Loews Hotels & Co's EBITDA, the noncontrolling interest share of EBITDA adjustments, gains or losses on asset acquisitions and dispositions, asset impairments, and equity method income, and including Loews Hotels & Co's pro rata Adjusted EBITDA of equity method investments. Pro rata Adjusted EBITDA of equity method investments is calculated by applying Loews Hotels & Co's ownership percentage to the underlying equity method investment's components of Adjusted EBITDA and excluding distributions in excess of basis.
The following table presents a reconciliation of Loews Hotels & Co net income attributable to Loews Corporation to its Adjusted EBITDA:
Three Months Ended March 31,
(In millions)
2026
2025
Loews Hotels & Co net income attributable to Loews Corporation
$ 26
$ —
Interest, net
12
13
Income tax expense
11
4
Depreciation and amortization
26
24
EBITDA
75
41
Noncontrolling interest share of EBITDA adjustments
(1)
Asset impairments
9
Equity investment adjustments:
Loews Hotels & Co's equity method income
(44)
(6)
Pro rata Adjusted EBITDA of equity method investments
83
46
Consolidation adjustments
1
1
Adjusted EBITDA
$ 124
$ 81
The following table presents a reconciliation of Loews Hotels & Co's equity method income to the Pro rata Adjusted EBITDA of its equity method investments:
Three Months Ended March 31,
(In millions)
2026
2025
Loews Hotels & Co's equity method income
$ 44
$ 6
Pro rata share of equity method investments:
Interest, net
17
10
Income tax expense
Depreciation and amortization
17
13
Asset impairments
9
Distributions in excess of basis
7
9
Other adjustments
(2)
(1)
Pro rata Adjusted EBITDA of equity method investments
May 04, 2026 07:00 ET | Source: Loblaw Companies Limited
TORONTO, May 04, 2026 (GLOBE NEWSWIRE) -- Loblaw Companies Limited (TSX: L; “Loblaw” or the “Company”) has partnered with Canadian technology firm Shakudo, as the Company continues to accelerate AI adoption to enhance its customer shopping experience and enhance its organizational capabilities. Shakudo’s platform enables companies to manage and scale AI, machine learning, and data infrastructure within complex technological environments. Loblaw will use this platform to build and run first-party AI applications, creating a centralized and consistent environment for its Digital and Technology & Analytics teams.
This partnership reflects Loblaw’s commitment to supporting Canadian innovation and technology, and marks another key milestone in the company’s ongoing efforts to increase its capabilities of rapidly deploying advanced systems and building ready-to-use tools internally.
“Speed matters, but standards matter more,” said Charu Pujari, Senior Vice President, Engineering and AI at Loblaw. “By partnering with Shakudo, we’ve given our teams a common platform to build on – so they can focus on solving real problems instead of reinventing core plumbing. It’s how we scale agentic capabilities responsibly, across many teams, without fragmentation.”
This partnership is central to how Loblaw builds AI: enabling faster development and consistent execution, while maintaining strict governance and oversight across all autonomous, agent-driven operations. As part of its AI integration strategy, Loblaw is establishing internal protocols that allow AI applications to securely interact with enterprise systems. Teams will use secure servers to coordinate AI-driven workflows, enhancing efficiency while maintaining governance and oversight.
“Loblaw is building exactly the kind of AI-native platform we designed Shakudo for,” said Yevgeniy Vahlis, Founder of Shakudo. “They’re not experimenting at the edges, they’re operationalizing agent orchestration at enterprise scale, with real standards, real workflows, and real impact. It’s exciting to see a Canadian company use Canadian AI technology as the backbone of such an ambitious effort.”
About Loblaw Companies Limited
Loblaw is Canada’s food and pharmacy leader, and the nation’s largest retailer. Loblaw provides Canadians with grocery, pharmacy, and healthcare services, other health and beauty products, apparel, general merchandise, financial services and wireless mobile products and services. With more than 2,800 locations, Loblaw, its franchisees and Associate-owners employ more than 220,000 full- and part-time employees, making it one of Canada’s largest private sector employers.
About Shakudo
Shakudo's operating system for AI helps enterprises accelerate their time to market with AI without ever sending their data out to third parties. By deploying within customers' own infrastructure, Shakudo delivers the flexibility of open-source tooling with enterprise-grade security—keeping sensitive data sovereign while unlocking AI capabilities across the organization.
Loews Corp (NYSE:L) reported lower first quarter 2026 earnings, with net income declining year-over-year amid weaker insurance underwriting results and higher corporate costs, even as its pipeline and hotel businesses posted gains.
Shares of the conglomerate, which has business interests in insurance, energy, hospitality and packaging, fell nearly 4% following the results.
For the quarter ended March 31, 2026, the company reported net income of $337 million, or $1.63 per diluted share, compared with $370 million, or $1.74 per share, in the same period a year earlier.
Revenue rose slightly to $4.56 billion from $4.49 billion.
The company said the decline in earnings was primarily driven by CNA Financial Corporation, where results were pressured by lower underlying underwriting performance and unfavorable prior-year reserve development, partially offset by higher net investment income.
Boardwalk Pipelines reported higher net income year-over-year, supported by stronger contracting rates and increased utilization-based revenue in gas transportation, along with improved pricing in storage, parking and lending services.
Loews Hotels also posted an increase in net income, reflecting higher equity income from joint ventures, particularly tied to the Universal Orlando Resort partnerships.
These gains were partly offset by weaker corporate segment results, which reflected lower investment income from the parent company’s trading portfolio as well as higher interest expenses.
Book value per share rose slightly to $90.90 as of March 31, 2026, compared with $90.71 at the end of 2025. Book value per share excluding accumulated other comprehensive income increased to $97.20 from $95.89 over the same period.
Loews reported $4.5 billion in cash and investments at the parent company level, alongside $1.8 billion in debt as of quarter-end.
The company also repurchased 0.3 million shares during the quarter for $31 million.
BRAMPTON, Ontario, May 06, 2026 (GLOBE NEWSWIRE) -- Loblaw Companies Limited (TSX: L) (“Loblaw” or the “Company”) announced today its unaudited financial results for the first quarter ended March 28, 2026(1).
Loblaw delivered a strong first quarter with positive sales momentum. Continued same-store sales growth in Food Retail, increased customer traffic, e-commerce sales growth, and new store openings drove topline performance. The Company's discount banners outperformed again, demonstrating that Canadians are responding well to greater access to Maxi and NoFrills® stores. E-commerce sales were led by growth in PC Express™ delivery, plus the successful integration of third-party delivery options. In Drug Retail, growth continued to reflect positive trends in prescription volumes, specialty drugs, and beauty categories. Drug Retail performance underscored the strength of the Company’s healthcare services and commitment to meeting the evolving needs of Canadians. Loblaw continued its focus on strategic expansion and innovation during the quarter, including opening 5 Hard Discount stores and 8 drug stores, bringing convenient access to nutritious food and essential healthcare services to more communities.
“We are very pleased that our strategic investments in opening new stores, and our focus on value, are resonating with Canadians and helping us to deliver strong financial results,” said Per Bank, President and Chief Executive Officer, Loblaw Companies Limited. “From the breadth of our banners and the continued growth of PC Express™ delivery, to the consistent strength of our pharmacy services, we are demonstrating our commitment to being there when and where our customers need us most.”
2026 FIRST QUARTER HIGHLIGHTS
Retail revenue was $14,484 million, an increase of $580 million, or 4.2%. Retail revenue increased by 4.5%, excluding the impact of revenue related to Wellwise by Shoppers (“Wellwise”) and the Theodore & Pringle® optical business. Food Retail (Loblaw) same-store sales increased by 2.4%.Drug Retail (Shoppers Drug Mart) same-store sales increased by 4.1%, with pharmacy and healthcare services same-store sales growth of 6.7% and front store same-store sales growth of 1.0%.E-commerce sales increased by 20.3%. Revenue (including Retail and PC Financial)(2) was $14,724 million, an increase of $589 million, or 4.2%.Retail gross profit percentage(2) of 31.4% was stable, decreasing by 10 basis points, primarily driven by changes in sales mix in Drug Retail categories, partially offset by continued improvements in shrink. Food Retail gross margin was flat.Retail operating income was $1,010 million, an increase of $172 million, or 20.5%.Retail adjusted EBITDA(2) was $1,607 million, an increase of $98 million, or 6.5%. Selling, general and administrative expenses (“SG&A”) as a percentage of sales was 20.3%, a decrease of 40 basis points. Net earnings available to common shareholders of the Company were $594 million, an increase of $91 million or 18.1%. Diluted net earnings per common share were $0.50, an increase of $0.08, or 19.0%. The increase included the impact of lower amortization related to certain intangible assets associated with the 2014 acquisition of Shoppers Drug Mart, which are now fully amortized.Adjusted net earnings available to common shareholders of the Company(2) were $609 million, an increase of $39 million, or 6.8%. Adjusted diluted net earnings per common share(2) were $0.52, an increase of $0.05, or 10.6%.Repurchased for cancellation 10.2 million common shares at a cost of $648 million. Gross capital investments were $312 million.Free cash flow(2) from Retail was $432 million, an increase of $729 million.In connection with the sale of PC Financial, Loblaw expects to receive approximately $600 million in cash, representing the release of excess capital, cash consideration from EQB Inc., and collection of certain commodity tax receivables.Quarterly common share dividend increased by 10%, marking the fifteenth consecutive year of dividend increases. CONSOLIDATED RESULTS OF OPERATIONS
The following table provides key performance metrics for the Company. Unless otherwise indicated, all financial information represents the Company’s results from continuing operations (Retail). PC Financial results are presented as discontinued operations.
For the periods ended March 28, 2026 and March 22, 2025 2026
2025
(millions of Canadian dollars except where otherwise indicated) (12 weeks) (12 weeks)Revenue $14,484 $13,904 Gross profit(2) $4,548 $4,384 Gross profit %(2) 31.4% 31.5%Operating income $1,010 $838 Adjusted operating income(2) 998 934 Adjusted EBITDA(2) $1,607 $1,509 Adjusted EBITDA margin(2) 11.1% 10.9%Net interest expense and other financing charges $181 $162 Adjusted net interest expense and other financing charges(2) 181 162 Earnings before income taxes $829 $676 Income taxes $217 $176 Adjusted income taxes(2) 214 205 Net earnings attributable to non-controlling interests $25 $19 Total Company Adjusted EBITDA(2) $1,687 $1,591 Continuing operations 1,607 1,509 Discontinued operations 80 82 Net earnings available to common shareholders of the Company $594 $503 Continuing operations 587 481 Discontinued operations 7 22 Adjusted net earnings available to common shareholders of the Company(2) $609 $570 Continuing operations 578 548 Discontinued operations 31 22 Diluted net earnings per common share(4)($) $0.50 $0.42 Continuing operations 0.50 0.40 Discontinued operations — 0.02 Adjusted diluted net earnings per common share(2),(4)($) $0.52 $0.47 Continuing operations 0.49 0.45 Discontinued operations 0.03 0.02 Diluted weighted average common shares outstanding(4)(in millions) 1,178.2 1,210.3 Revenue represents retail revenue, and is primarily comprised of Food Retail and Drug Retail sales. The following table provides a breakdown of the Company’s total and same-store sales.
For the periods ended March 28, 2026 and March 22, 2025 2026 2025 (millions of Canadian dollars except where otherwise indicated) (12 weeks) (12 weeks) SalesSame-store
sales SalesSame-store
sales Sales
$ ChangeSales
% ChangeFood Retail(i) $ 10,238 2.4 % $9,8542.2% $3843.9%Drug Retail 4,246 4.1 % 4,0503.8% 1964.8 %Pharmacy and healthcare services 2,384 6.7 % 2,2016.4% 1838.3 %Front store 1,862 1.0 % 1,8490.9% 130.7 %Revenue $ 14,484 $13,904 $5804.2 %PC Financial revenue (discontinued operations) 240 231 93.9 %Revenue (including Retail and PC Financial) $ 14,724 $14,135 $5894.2 % (i)As a result of the announcement of the sale of PC Financial, Food Retail sales now includes revenue related to PC Services, primarily related to sales attributable to The Mobile Shop™ in the current and comparative period presented, including revenue of $69 million in the first quarter of 2026 (2025 – $67 million). RETAIL RESULTS (CONTINUING OPERATIONS)
In the first quarter of 2026, Retail revenue was $14,484 million, an increase of $580 million, or 4.2%. Retail revenue increased by 4.5%, excluding the impact of revenue related to Wellwise and the Theodore & Pringle® optical business. Food Retail (Loblaw) sales were $10,238 million, an increase of $384 million, and same-store sales grew by 2.4% (2025 – 2.2%). The Company’s internal food inflation was significantly lower than the Consumer Price Index for Food Purchased From Stores of 4.4% (2025 – 2.6%); andFood Retail traffic increased and basket size increased on a same-store sales basis. Drug Retail (Shoppers Drug Mart) sales were $4,246 million, an increase of $196 million, and same-store sales grew by 4.1% (2025 – 3.8%). Pharmacy and healthcare services same-store sales growth was 6.7% (2025 – 6.4%), led by specialty prescriptions. On a same-store basis, the number of prescriptions increased by 2.8% (2025 – 2.3%) and the average prescription value increased by 5.0% (2025 – 4.4%).Front store same-store sales growth was 1.0% (2025 – 0.9%), primarily driven by higher sales of beauty products, with performance moderated by a shift in timing of the cough, cold, and flu season, and inclement weather. The sale of Wellwise and the wind-down of the Theodore & Pringle® optical business were completed in 2025. Revenue related to Wellwise and the optical business in the first quarter of 2026 was nil (2025 – $21 million and $18 million, respectively).In the first quarter of 2026, 13 food and drug stores were opened and 2 food and drug stores were closed. Retail square footage was 73.5 million square feet, a net increase of 1.2 million square feet, or 1.7%, compared to the first quarter of 2025. Gross profit(2) in the first quarter of 2026 was $4,548 million, an increase of $164 million, or 3.7%. Gross profit percentage(2) of 31.4% was stable, decreasing by 10 basis points, primarily driven by changes in sales mix in Drug Retail categories, partially offset by continued improvements in shrink. Food Retail gross margin was flat.Operating income in the first quarter of 2026 was $1,010 million, an increase of $172 million, or 20.5%.Adjusted EBITDA(2) in the first quarter of 2026 was $1,607 million, an increase of $98 million, or 6.5%. The increase was driven by an increase in gross profit(2), partially offset by an increase in SG&A. SG&A as a percentage of sales was 20.3%, a favourable decrease of 40 basis points, primarily due to operating leverage from higher sales and the timing of certain costs, partially offset by incremental costs related to opening new stores and the automated distribution facility.Depreciation and amortization in the first quarter of 2026 was $619 million, a decrease of $72 million, or 10.4%, primarily driven by the impact of lower amortization related to certain intangible assets associated with the 2014 acquisition of Shoppers Drug Mart Corporation (“Shoppers Drug Mart”), which are now fully amortized, partially offset by an increase in depreciation of leased assets and fixed assets related to opening new stores and the automated distribution facility. Included in depreciation and amortization was the amortization of intangible assets related to the acquisitions of Shoppers Drug Mart and Lifemark Health Group (“Lifemark”) of $10 million (2025 – $116 million). PC FINANCIAL RESULTS (DISCONTINUED OPERATIONS)
As previously announced in 2025, the Company entered into an agreement with EQB Inc. (“EQB”) pursuant to which EQB will acquire President’s Choice Bank (“PC Bank”) and certain other affiliated entities (collectively, “PC Financial”) (the “Sale of PC Financial”). EQB will acquire PC Financial for consideration satisfied through a combination of 7.2 million EQB shares and cash, subject to adjustment pursuant to the terms of the agreement.
Subsequent to the end of the first quarter of 2026, the Company and EQB announced that they obtained all required regulatory approvals for the Sale of PC Financial. The transaction is anticipated to close in the Company's third quarter of 2026, subject to customary closing conditions.
Upon closing, the Company will begin to recognize its proportionate share of EQB’s net income within its consolidated financial results. The Company and EQB have different fiscal year and quarter ends. As a result of this difference, the Company will recognize its proportionate share of EQB’s net income based on the most recent publicly available information at each of the Company’s fiscal year and quarter end dates.
As a result of the announcement of the sale of PC Financial to EQB, the results of PC Financial are presented in discontinued operations, net of intersegment eliminations.
Revenue, included in discontinued operations, in the first quarter of 2026 was $240 million, an increase of $9 million, or 3.9%. The increase was primarily driven by higher interest and interchange income, and higher insurance commission income.Net earnings available to common shareholders of the Company from discontinued operations were $7 million, a decrease of $15 million. The decrease was primarily driven by a charge of $24 million due to a change in certain commodity tax legislation, and higher charge-offs, partially offset by higher revenue described above, and the year-over-year favourable impact of expected credit loss provision. OUTLOOK(3)
Loblaw will continue to execute on retail excellence while advancing its growth initiatives with the goal of delivering consistent operational and financial results in 2026. The Company’s businesses remain well positioned to meet the everyday needs of Canadians. The Company cannot predict the timing of the closing of the Sale of PC Financial, and its impact on the Company’s financial results. In 2026, excluding this impact and the 53rd week impact in 2025, the Company continues to expect:
its Retail business to grow earnings faster than sales;adjusted net earnings per common share(2) growth in the high single-digits;to continue investing in our store network and distribution centres by investing approximately $2.4 billion in gross capital expenditures; andto return capital to shareholders by allocating a significant portion of free cash flow to share repurchases. NORMAL COURSE ISSUER BID PROGRAM (“NCIB”)
During the first quarter of 2026, the Company repurchased 10.2 million common shares for cancellation at a cost of $648 million.
From time to time, the Company participates in an automatic share purchase plan (“ASPP”) with a broker in order to facilitate the repurchase of the Company’s common shares under its NCIB. During the effective period of the ASPP, the Company’s broker may purchase common shares at times when the Company would not be active in the market.
DECLARATION OF DIVIDENDS
Subsequent to the end of the first quarter of 2026, the Board of Directors declared a quarterly dividend of $0.155183 per common share, payable on July 1, 2026 to shareholders of record on June 15, 2026, an increase of 10% from the previous quarterly dividend of $0.141075 per common share paid on April 1, 2026.
NON-GAAP AND OTHER FINANCIAL MEASURES
The Company uses the following non-GAAP and other financial measures and ratios: Adjusted earnings before income taxes, net interest expense and other financing charges and depreciation and amortization (“adjusted EBITDA”); adjusted EBITDA margin; adjusted operating income; adjusted net interest expense and other financing charges; adjusted income taxes; adjusted effective tax rate; adjusted net earnings available to common shareholders; adjusted diluted net earnings per common share, revenue (including Retail and PC Financial), free cash flow, and same-store sales. The Company believes these non-GAAP and other financial measures and ratios provide useful information to both management and investors in measuring the financial performance and financial condition of the Company for the reasons outlined below.
Management uses these and other non-GAAP and other financial measures to exclude the impact of certain expenses and income that must be recognized under GAAP when analyzing underlying consolidated operating performance, as the excluded items are not necessarily reflective of the Company’s underlying operating performance and make comparisons of underlying financial performance between periods difficult. The Company adjusts for these items if it believes doing so would result in a more effective analysis of underlying operating performance. The exclusion of certain items does not imply that they are non-recurring.
These measures do not have a standardized meaning prescribed by GAAP and therefore they may not be comparable to similarly titled measures presented by other publicly traded companies and should not be construed as an alternative to other financial measures determined in accordance with GAAP.
As a result of the announcement of the sale of PC Financial, the results of PC Financial, net of intersegment eliminations, are presented separately as discontinued operations in the Company’s current and comparative results. Unless otherwise indicated, all financial information represents the Company’s results from continuing operations (Retail).
Summary of Non-GAAP and Other Financial Measures
The following table provides a summary of the differences between the Company’s consolidated GAAP and Non-GAAP and other financial measures.
For the periods ended March 28, 2026 and March 22, 2025 2026 2025(millions of Canadian dollars except where otherwise indicated) (12 weeks) (12 weeks) GAAP Adjusting
ItemsNon-
GAAP(2) GAAP Adjusting
ItemsNon-
GAAP(2)EBITDA $ 1,629 $ (22)$ 1,607 $1,529 $(20)$1,509Operating income $ 1,010 $ (12)$ 998 $838 $96 $934Net interest expense and other financing charges 181 — 181 162 — 162Earnings before income taxes $ 829 $ (12)$ 817 $676 $96 $772Deduct (add) the following: Income taxes 217 (3) 214 176 29 205Non-controlling interests 25 — 25 19 — 19Net earnings available to common shareholders of the Company from continuing operations $ 587 $ (9)$ 578 $481 $67 $548Net earnings available to common shareholders of the Company from discontinued operations 7 24 31 22 — 22Net earnings available to common shareholders of the Company $ 594 $ 15 $ 609 $503 $67 $570Diluted net earnings per common share(4) ($) $ 0.50 $ 0.02 $ 0.52 $0.42 $0.05 $0.47Continuing operations 0.50 (0.01) 0.49 0.40 0.05 0.45Discontinued operations — 0.03 0.03 0.02 — 0.02Diluted weighted average common shares(4) (millions) 1,178.2 — 1,178.2 1,210.3 — 1210.3 Adjusted Operating Income, Adjusted EBITDA and Adjusted EBITDA Margin The following table reconciles adjusted operating income and adjusted EBITDA to operating income, which is reconciled to net earnings attributable to shareholders of the Company from continuing operations as reported in the condensed consolidated statements of earnings for the periods ended as indicated. The Company believes that adjusted EBITDA is useful in assessing the performance of its ongoing operations and its ability to generate cash flows to fund its cash requirements, including the Company’s capital investment program.
Adjusted EBITDA margin is calculated as adjusted EBITDA divided by revenue.
For the periods ended March 28, 2026 and March 22, 2025 2026 2025 (millions of Canadian dollars) (12 weeks)
(12 weeks) Net earnings attributable to shareholders of the Company from continuing operations $ 587 $481 Add impact of the following: Non-controlling interests 25 19 Net interest expense and other financing charges 181 162 Income taxes 217 176 Operating income $ 1,010 $838 Add (deduct) impact of the following: Amortization of intangible assets acquired with Shoppers Drug Mart and Lifemark $ 10 $116 PC Financial transaction costs 1 — Sale of Wellwise — (5)Gain on sale of non-operating property — (14)Fair value adjustment on fuel, foreign currency contracts and investments (23) (1)Adjusting items $ (12) $96 Adjusted operating income $ 998 $934 Depreciation and amortization 619 691 Less: Amortization of intangible assets acquired with Shoppers Drug Mart and Lifemark (10) (116)Adjusted EBITDA $ 1,607 $1,509 Adjusted EBITDA was impacted by the following:
Amortization of intangible assets acquired with Shoppers Drug Mart and Lifemark The acquisition of Shoppers Drug Mart in 2014 included approximately $6,050 million of definite life intangible assets, which are being amortized over their estimated useful lives. The annual amortization associated with the acquired intangibles will be approximately $30 million in 2026 and thereafter.
The acquisition of Lifemark in 2022 included approximately $299 million of definite life intangible assets, which are being amortized over their estimated useful lives.
PC Financial transaction costs In the first quarter of 2026, the Company recorded transaction and other related costs of $1 million in connection with the Sale of PC Financial.
Sale of Wellwise In the fourth quarter of 2024, the Company entered into an agreement with a third party to sell all of the shares of its Wellwise business, including 42 Wellwise locations, for cash proceeds and recorded a net fair value write-down of $23 million in SG&A. The transaction closed in the first quarter of 2025 and the Company recorded a gain of $5 million in SG&A.
Gain on sale of non-operating property In the first quarter of 2025, the Company recorded a gain related to the sale of a non-operating property to a third party of $14 million.
Fair value adjustment on fuel, foreign currency contracts, and investments The Company is exposed to commodity price and U.S. dollar exchange rate fluctuations. In accordance with the Company’s commodity risk management policy, the Company enters into exchange traded futures contracts and forward contracts to minimize cost volatility relating to fuel prices and the U.S. dollar exchange rate. These derivatives are not acquired for trading or speculative purposes. Pursuant to the Company’s derivative instruments accounting policy, changes in the fair value of these instruments, which include realized and unrealized gains and losses, are recorded in operating income. Despite the impact of accounting for these commodity and foreign currency derivatives on the Company’s reported results, the derivatives have the economic impact of largely mitigating the associated risks arising from price and exchange rate fluctuations in the underlying commodities and U.S. dollar commitments. The Company holds certain investments, including Venture Fund investments, classified as fair value through profit and loss. Any changes in the fair value of these investments are included in operating income. Starting in the first quarter of 2026, fair value adjustments on such investments are considered an adjusting item. See Section 11 “Non-GAAP and Other Financial Measures” of the Company’s Management’s Discussion and Analysis in the Company’s 2026 First Quarter Report to Shareholders for details regarding the impact of this change to certain Non-GAAP measures.
Adjusted Operating Income from Discontinued Operations, Total Company Adjusted Operating Income, Adjusted EBITDA from Discontinued Operations, Total Company Adjusted EBITDA and Total Company Adjusted EBITDA Margin The following table reconciles adjusted operating income and adjusted EBITDA from discontinued operations to operating income from discontinued operations which is reconciled to net earnings attributable to shareholders of the Company from discontinued operations as reported in the condensed consolidated statements of earnings for the periods ended as indicated. The Company believes that adjusted EBITDA from discontinued operations and on a total Company basis is useful in assessing the performance of its total Company and discontinued operations and its ability to generate cash flows to fund its cash requirements, including the Company’s capital investment program.
Total Company adjusted EBITDA margin is calculated as total Company adjusted EBITDA divided by revenue (including Retail and PC Financial).
For the periods ended March 28, 2026 and March 22, 2025 2026 2025(millions of Canadian dollars) (12 weeks)
(12 weeks)Net earnings attributable to shareholders of the Company from discontinued operations(i) $7 $22Add impact of the following: Net interest expense and other financing charges(i) 46 36Income taxes(i) 4 10Operating income from discontinued operations(i) $57 $68Add impact of the following: Charge related to PC Bank commodity tax matter $23 $—Adjusting items $23 $—Adjusted operating income from discontinued operations $80 $68Adjusted operating income (refer to table above) 998 934Total Company adjusted operating income $1,078 $1,002Adjusted operating income from discontinued operations $80 $68Depreciation and amortization from discontinued operations — 14Adjusted EBITDA from discontinued operations $80 $82Adjusted EBITDA (refer to table above) 1,607 1,509Total Company Adjusted EBITDA $1,687 $1,591 (i)For additional information, see note 4 “Assets Held for Sale and Discontinued Operations” of the Company’s interim financial statements. In addition to the items described in the adjusted EBITDA(2) section above, adjusted operating income from discontinued operations and Total Company adjusted operating income were impacted by the following:
Charge related to PC Bank commodity tax matter In the first quarter of 2026, the Federal government enacted commodity tax legislation rendering PC Bank ineligible to claim notional input tax credits for certain payments it makes to Loblaws Inc. in respect of redemptions of loyalty points. As the legislation was effective beginning in fiscal year 2025, PC Bank recorded a charge of $23 million in SG&A, reversing notional input tax credit related amounts previously recorded. In addition, a charge of $10 million was recorded, reversing interest income on expected cash tax refunds.
Adjusted Net Interest Expense and Other Financing Charges The following table reconciles adjusted net interest expense and other financing charges to net interest expense and other financing charges as reported in the condensed consolidated statements of earnings for the periods ended as indicated. The Company believes that adjusted net interest expense and other financing charges is useful in assessing the Company’s underlying financial performance and in making decisions regarding the financial operations of the business.
For the periods ended March 28, 2026 and March 22, 2025 2026 2025(millions of Canadian dollars) (12 weeks)
(12 weeks)Net interest expense and other financing charges $ 181 $162Adjusted net interest expense and other financing charges $ 181 $162 Adjusted Net Interest Expense and Other Financing Charges from Discontinued Operations The following table reconciles adjusted net interest expense and other financing charges from discontinued operations to adjusted net interest expense and other financing charges from discontinued operations as reported in the notes to the interim financial statements for the periods ended as indicated. The Company believes that adjusted net interest expense and other financing charges is useful in assessing the Company’s underlying financial performance and in making decisions regarding the financial operations of the business.
For the periods ended March 28, 2026 and March 22, 2025 2026 2025(millions of Canadian dollars)(12 weeks)
(12 weeks)Net interest expense and other financing charges from discontinued operations(i) $ 46 $36Deduct: Charge related to PC Bank commodity tax matter (10) —Adjusted net interest expense and other financing charges from discontinued operations $ 36 $36 (i)For additional information, see note 4 “Assets Held for Sale and Discontinued Operations” of the Company’s interim financial statements. Charge related to PC Bank commodity tax matter In the first quarter of 2026, a charge of $10 million was recorded, reversing interest income on expected cash tax refunds on the PC Bank commodity tax matter as discussed above.
Adjusted Income Taxes and Adjusted Effective Tax Rate The following table reconciles adjusted income taxes to income taxes as reported in the condensed consolidated statements of earnings for the periods ended as indicated. The Company believes that adjusted income taxes is useful in assessing the Company’s underlying operating performance and in making decisions regarding the ongoing operations of its business.
Adjusted effective tax rate is calculated as adjusted income taxes divided by the sum of adjusted operating income less adjusted net interest expense and other financing charges.
For the periods ended March 28, 2026 and March 22, 2025 2026
2025
(millions of Canadian dollars except where otherwise indicated) (12 weeks)
(12 weeks)Adjusted operating income(i) $998 $934 Adjusted net interest expense and other financing charges(i) 181 162 Adjusted earnings before taxes $817 $772 Income taxes $217 $176 Add impact of the following: Tax impact of items included in adjusted earnings before taxes(ii) (3) 29 Adjusted income taxes $214 $205 Effective tax rate 26.2% 26.0%Adjusted effective tax rate 26.2% 26.6% (i)See reconciliations of adjusted operating income and adjusted net interest expense and other financing charges in the tables above.(ii)See the adjusted operating income, adjusted EBITDA and adjusted EBITDA margin table and the adjusted net interest expense and other financing charges table above for a complete list of items included in adjusted earnings before taxes. Adjusted Net Earnings Available to Common Shareholders From Continuing Operations and Adjusted Diluted Net Earnings Per Common Share From Continuing Operations The following table reconciles adjusted net earnings available to common shareholders of the Company from continuing operations and adjusted net earnings attributable to shareholders of the Company from continuing operations to net earnings attributable to shareholders of the Company and then to net earnings available to common shareholders of the Company from continuing operations as reported in the condensed consolidated statements of earnings for the periods ended as indicated. The Company believes that adjusted net earnings available to common shareholders from continuing operations and adjusted diluted net earnings per common share from continuing operations are useful in assessing the Company’s underlying operating performance and in making decisions regarding the ongoing operations of its business.
For the periods ended March 28, 2026 and March 22, 2025 2026 2025(millions of Canadian dollars except where otherwise indicated) (12 weeks)
(12 weeks)Net earnings attributable to shareholders of the Company $ 594 $503Net earnings from discontinued operations 7 22Net earnings attributable to shareholders of the Company from continuing operations $ 587 $481Net earnings available to common shareholders of the Company from continuing operations $ 587 $481Net earnings attributable to shareholders of the Company from continuing operations $ 587 $481Adjusting items (refer to the following table) (9) 67Adjusted net earnings attributable to shareholders of the Company from continuing operations $ 578 $548Adjusted net earnings available to common shareholders of the Company from continuing operations $ 578 $548Diluted weighted average common shares outstanding(4) (millions) 1,178.2 1,210.3 The following table reconciles adjusted net earnings available to common shareholders of the Company and adjusted diluted net earnings per common share to net earnings available to common shareholders of the Company and diluted net earnings per common share as reported in the condensed consolidated statements of earnings for the periods ended as indicated.
2026 2025 (12 weeks) (12 weeks) Net Earnings
Available to
Common
Shareholders
of the
Company Diluted
Net
Earnings
Per
Common
Share Net Earnings
Available to
Common
Shareholders
of the
Company Diluted
Net
Earnings
Per
Common
Share(4)For the periods ended March 28, 2026 and March 22, 2025
(millions of Canadian dollars/Canadian dollars) Continuing operations $587 $0.50 $481 $0.40 Discontinued operations 7 — 22 0.02 As reported $594 $0.50 $503 $0.42 Continuing operations $587 $0.50 $481 $0.40 Add (deduct) impact of the following: Amortization of intangible assets acquired with Shoppers Drug Mart and Lifemark $7 $— $86 $0.07 PC Financial transaction costs 1 — — — Sale of Wellwise — — (5) (0.01)Gain on sale of non-operating property — — (13) (0.01)Fair value adjustment on fuel, foreign currency contracts, and investments (17) (0.01) (1) — Adjusting items from continuing operations $(9) $(0.01) $67 $0.05 Adjusted continuing operations $578 $0.49 $548 $0.45 Discontinued operations $7 $— $22 $0.02 Add impact of the following: Charges related to PC Bank commodity tax matter $24 $0.03 $— $— Adjusting items from discontinued operations $24 $0.03 $— $— Adjusted discontinued operations $31 $0.03 $22 $0.02 Adjusted Total Company $609 $0.52 $570 $0.47 Revenue (including Retail and PC Financial) The following table reconciles Revenue (including Retail and PC Financial) to Revenue for the periods ended as indicated. Revenue represents retail revenue, and is primarily comprised of Food Retail and Drug Retail sales. The Company believes that Revenue (including Retail and PC Financial) are useful in assessing the Company’s underlying operating performance.
For the periods ended March 28, 2026 and March 22, 2025 2026 2025(millions of Canadian dollars except where otherwise indicated) (12 weeks) (12 weeks)Food Retail(i) $10,238 $9,854Drug Retail 4,246 4,050Pharmacy and healthcare services 2,384 2,201Front store 1,862 1,849Revenue $14,484 $13,904PC Financial revenue (discontinued operations) $240 $231Revenue (including Retail and PC Financial) $14,724 $14,135 (i)As a result of the announcement of the sale of PC Financial, Food Retail sales now includes revenue related to PC Services, primarily related to sales attributable to The Mobile Shop™ in the current and comparative period presented, including revenue of $69 million in the first quarter of 2026 (2025 – $67 million). Free Cash Flow The following table reconciles cash flows from operating activities to free cash flow. The Company believes that free cash flow is the appropriate measure in assessing the Company’s cash available for additional financing and investing activities.
2026 2025 (12 weeks) (12 weeks)For the periods ended March 28, 2026 and March 22, 2025 Continuing Operations
Discontinued Operations
Total
Continuing Operations
Discontinued Operations
Total
(millions of Canadian dollars) Cash flows from operating activities $ 1,096 $ 212 $ 1,308 $412 $541 $953Less: Capital investments(i) 305 7 312 237 9 246Interest paid 87 16 103 87 20 107Lease payments, net 272 — 272 385 — 385Free cash flow(2) $ 432 $ 189 $ 621 $(297) $512 $215 (i) Capital investments are the sum of fixed asset purchases and intangible asset additions as presented in the Company’s condensed consolidated statements of cash flows, and prepayments transferred to fixed assets in the current period. Same-Store Sales Same-store sales are retail sales for stores in operation in both comparable periods, including relocated, converted, expanded, contracted or renovated stores. The Company believes this metric is useful in assessing sales trends excluding the effect of the opening and closure of stores.
FORWARD-LOOKING STATEMENTS
This News Release contains forward-looking statements about the Company’s objectives, plans, goals, aspirations, strategies, financial condition, results of operations, cash flows, performance, prospects, opportunities and legal and regulatory matters. Specific forward-looking statements in this News Release include, but are not limited to, statements with respect to the Company’s anticipated future results, events and plans, strategic initiatives and restructuring, regulatory changes including further healthcare reform, future liquidity, planned capital investments, and the status and impact of IT systems implementations. These specific forward-looking statements are contained throughout this News Release including, without limitation, in the “Consolidated Results of Operations”, “Retail Results (Continuing Operations)”, “PC Financial Results (Discontinued Operations)”, and “Outlook” sections of this News Release. Forward-looking statements are typically identified by words such as “expect”, “anticipate”, “believe”, “foresee”, “could”, “estimate”, “goal”, “intend”, “plan”, “seek”, “strive”, “will”, “may”, “should” and similar expressions, as they relate to the Company and its management.
Forward-looking statements reflect the Company’s estimates, beliefs and assumptions, which are based on management’s perception of historical trends, current conditions and expected future developments, as well as other factors it believes are appropriate in the circumstances. The Company’s estimates, beliefs and assumptions are inherently subject to significant business, economic, competitive and other uncertainties and contingencies regarding future events and, as such, are subject to change. The Company can give no assurance that such estimates, beliefs and assumptions will prove to be correct.
Numerous risks and uncertainties could cause the Company’s actual results to differ materially from those expressed, implied or projected in the forward-looking statements, including those described in the Company’s Management Discussion & Analysis (“MD&A”) in the 2025 Annual Report, and the Company’s Annual Information Form (“AIF”) for the year ended January 3, 2026.
Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect the Company’s expectations only as of the date of this News Release. Except as required by law, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CORPORATE PROFILE
2025 Annual Report and 2026 First Quarter Report to Shareholders
The Company’s 2025 Annual Report and 2026 First Quarter Report to Shareholders are available in the “Investors” section of the Company’s website at loblaw.ca and sedarplus.ca.
InvestorsMediaRoy MacDonaldScott BonikowskyVice President, Investor RelationsSenior Vice President, Corporate Affairs and [email protected]@loblaw.ca Additional financial information has been filed electronically with various securities regulators in Canada through SEDAR+ and with the Office of the Superintendent of Financial Institutions (OSFI) as the primary regulator for the Company’s subsidiary, PC Bank. The Company holds an analyst call shortly following the release of its quarterly results. These calls are archived in the “Investors” section of the Company’s website at loblaw.ca.
Conference Call and Webcast
Loblaw will host a conference call as well as an audio webcast on May 6, 2026 at 10:00 a.m. (ET).
To access via audio webcast please go to the “Investors” section of loblaw.ca, and note that pre-registration will be available. Alternatively, please dial (647) 932-3411 or Toll-Free (800) 715-9871. Following the live event, the webcast will be archived and available to replay for 12 months.
Full details about the conference call and webcast are available on the Loblaw website at loblaw.ca.
Annual Meeting of Shareholders
The 2026 Annual Meeting of Shareholders of Loblaw Companies Limited will be held on Tuesday, May 12, 2026 at 10:00 a.m. (ET) at Massey Hall, 178 Victoria Street, Toronto, Ontario, Canada and virtually via a live webcast.
Shareholders will also be able to listen, participate and vote at the meeting in real time through a live webcast online at https://meetings.lumiconnect.com/400-240-280-696 (meeting password: agm2026). See “Questions and answers on attending and voting virtually” in the Management Proxy, which can be viewed online at www.loblaw.ca or under Loblaw’s SEDAR+ profile at www.sedarplus.ca, for detailed instructions on how to attend and vote at the meeting.
Please refer to the “Events and Presentations” or “Shareholders Services” page at loblaw.ca for additional details on the virtual meeting.
News Release Endnotes (1) This News Release contains forward-looking information. See “Forward-Looking Statements” section of this News Release and the Company’s 2026 First Quarter Report to Shareholders for a discussion of material factors that could cause actual results to differ materially from the forecasts and projections herein and of the material factors and assumptions that were used when making these statements. This News Release should be read in conjunction with Loblaw Companies Limited’s filings with securities regulators made from time to time, all of which can be found at sedarplus.ca and at loblaw.ca.
(2) See “Non-GAAP and Other Financial Measures” section of this News Release, which includes the reconciliation of such non-GAAP and other financial measures to the most directly comparable GAAP measures.
(3) To be read in conjunction with the “Forward-Looking Statements” section of this News Release and the Company’s 2026 First Quarter Report to Shareholders.
(4) Adjusted to reflect the four-for-one stock split effective at the close of business on August 18, 2025. For additional information, see note 10 “Share Capital” of the Company’s interim financial statements.
May 06, 2026 06:45 ET | Source: Loblaw Companies Limited
BRAMPTON, Ontario, May 06, 2026 (GLOBE NEWSWIRE) -- (TSX: L) – Loblaw Companies Limited (Loblaw) announced today that the Toronto Stock Exchange (TSX) has accepted a notice filed by Loblaw of its intention to make a normal course issuer bid (NCIB).
The TSX notice provides that Loblaw may, during the 12-month period commencing May 8, 2026 and terminating May 7, 2027, purchase up to 58,124,733 of Loblaw’s common shares (Common Shares), representing approximately 5% of the issued and outstanding Common Shares, by way of a NCIB on the TSX or through alternative trading systems or by such other means as may be permitted by the TSX or under applicable law. As of April 30, 2026, Loblaw had 1,162,494,675 outstanding Common Shares. Based on the average daily trading volume of 1,248,481 during the last six months, daily purchases will be limited to 312,120 Common Shares, other than block purchase exceptions and purchases from George Weston Limited (GWL), Loblaw’s majority shareholder.
In accordance with an exemption granted by the TSX pursuant to its rules, regulations and policies in connection with the NCIB, GWL will participate in the NCIB on a basis proportionate to its percentage ownership interest in Loblaw, which is consistent with the exemption granted by the TSX each year since 2020. Such participation eliminates the accretive effect that the NCIB would otherwise have on GWL’s percentage ownership interest in Loblaw. The maximum number of Common Shares that may be purchased pursuant to the NCIB will be reduced by the number of Common Shares purchased by Loblaw from GWL.
Purchases of Common Shares will be made in open market transactions on the TSX or through alternative trading systems. In addition, Loblaw may enter into forward purchase or swap contracts in connection with Common Shares which may be settled by physical settlement, cash settlement or a combination thereof, in each case subject to regulatory approval, if required, and on such terms and at such times as shall be permitted by applicable securities laws. The forward price will be based on market price, dividend yield and market interest rates. Loblaw may also purchase Common Shares through private agreements or share repurchase programs if it receives an issuer bid exemption order permitting it to make such purchases. Any purchases of Common Shares made by way of private agreements or under share repurchase programs may be at a discount to the prevailing market price as provided in the relevant issuer bid exemption order.
Purchases from GWL will be made during the TSX’s Special Trading Session pursuant to an automatic disposition plan agreement between Loblaw’s broker, Loblaw and GWL (ADP Agreement). Purchases from GWL will be made on trading days, as required by the ADP Agreement, that Loblaw makes a purchase from other shareholders. In the event that GWL does not sell Common Shares on any trading day as required by the terms of the ADP Agreement (other than as a result of a market disruption event), the TSX exemption will cease to apply and Loblaw will not be permitted to make any further purchases from GWL under the terms of the NCIB.
Decisions regarding the timing of future purchases of Common Shares will be based on market conditions, share price and other factors. Loblaw may elect to suspend or discontinue its NCIB at any time, subject to the terms of any automatic purchase plan then in place. Common Shares purchased under the NCIB will be cancelled or used in connection with the settlement of restricted share units or performance share units. Loblaw believes that the market price of Common Shares could be such that their purchase may be an attractive and appropriate use of corporate funds. Loblaw may also use its NCIB to acquire the number of Common Shares that are issued pursuant to the exercise of options in order to offset the dilutive effect of options that have been exercised. Under its prior NCIB that commenced on May 6, 2025 and expired on May 5, 2026, Loblaw had sought and received approval from the TSX to purchase up to 59,800,244 Common Shares. As of April 30, 2026, Loblaw has purchased 36,885,504 Common Shares under its prior NCIB through open market purchases on the TSX and exempt private agreement purchases, at a weighted average price of $59.85.
From time to time, when Loblaw does not possess material non-public information about itself or its securities, it may enter into a pre-defined plan with its broker to allow for the purchase of Common Shares at times when Loblaw ordinarily would not be active in the market due to its own internal trading blackout periods and insider trading rules. Any such plans entered into with Loblaw’s broker will be adopted in accordance with the requirements of applicable Canadian securities laws. Loblaw intends to enter an automatic share purchase plan with a broker on or about May 8, 2026, in order to facilitate repurchases under the NCIB.
About Loblaw Companies Limited
Loblaw is Canada's food and pharmacy leader, and the nation's largest retailer. Loblaw provides Canadians with grocery, pharmacy and health services, other health and beauty products, apparel, general merchandise, financial services and wireless mobile products and services. With more than 2,800 locations, Loblaw, its franchisees and Associate-owners employ more than 220,000 full- and part-time employees, making it one of Canada's largest private sector employers.
Loblaw's purpose – Live Life Well® – puts first the needs and well-being of Canadians who make one billion transactions annually in the company's stores. Loblaw is positioned to meet and exceed those needs in many ways: convenient locations; more than 1,100 grocery stores that span the value spectrum from discount to specialty; full-service pharmacies at nearly 1,400 Shoppers Drug Mart® and Pharmaprix® locations and in close to 500 grocery stores; PC Financial® services; affordable Joe Fresh® fashion and family apparel; and four of Canada's top-consumer brands in Life Brand®, Farmer’s Market™, no name® and President's Choice®. For more information, visit Loblaw's website at www.loblaw.ca and Loblaw's issuer profile at www.sedarplus.ca.
For more information contact: Roy MacDonald, Vice President, Investor Relations, (905) 861-2243, [email protected]
May 12, 2026 07:00 ET | Source: Loblaw Companies Limited
BRAMPTON, Ontario, May 12, 2026 (GLOBE NEWSWIRE) -- Loblaw Companies Limited (TSX: L) released its 2025 Live Life Well® report, highlighting the Company’s continued progress across environmental, social, and governance (ESG) priorities.
As a proudly Canadian food and health care company, Loblaw remains committed to helping Canadians prosper today and for generations to come. This commitment is reflected in ongoing efforts to address climate change, advance social equity, and support communities across the country.
“As a generational Canadian company, we are deeply rooted in the communities we serve,” said Per Bank, President and CEO, Loblaw Companies Limited. “Across more than 2,800 stores, our Franchisee Owners, Associate Owners, Managers, Pharmacists and colleagues live where they work. They understand the realities facing their neighbours, and that proximity shapes how we respond to social challenges, climate impacts, and the everyday needs of the millions of Canadians who rely on us.”
In 2025, Loblaw continued to advance its ESG priorities through initiatives that included improving food access, advancing responsible sourcing, strengthening climate resilience, and supporting health equity.
Key highlights from 2025 include:
Reduced food waste by donating more than 20,000 metric tonnes of food to food banks and recovery organizations. Strengthened responsible sourcing efforts through ongoing partnerships with Canadian suppliers and initiatives that aim to protect ecosystems. Advanced climate action by investing in renewable energy, reducing emissions, and redesigning packaging to improve the recyclability of thousands of products.Raised and donated more than $23.7 million to President’s Choice Children’s Charity, supporting school food programs that reached one million children. Raised and donated more than $18.7 million to the Shoppers Foundation for Women’s Health, supporting health equity for all women in Canada. Opened 250 Pharmacy Care Clinics, improving access to care in the communities we serve. Read the full 2025 Live Life Well® report at https://www.loblaw.ca/en/responsibility/.
NEW YORK, May 12, 2026 /PRNewswire/ -- Loews Corporation (NYSE: L) announced today the declaration of the Company's quarterly dividend of $0.0625 per share of Common Stock, payable June 9, 2026 to shareholders of record as of the close of business on May 27, 2026.
Loews Corporation is a diversified company with businesses in the insurance, energy, hospitality, and packaging industries. For more information please visit www.loews.com.
May 12, 2026 21:40 ET | Source: Loblaw Companies Limited
BRAMPTON, Ontario, May 12, 2026 (GLOBE NEWSWIRE) -- (TSX: L) – Loblaw Companies Limited (Loblaw) announced today that all of the nominee directors listed in the management proxy circular dated March 30, 2026, were elected as directors of Loblaw. The vote was conducted at the Company's Annual Meeting of Shareholders, held at Massey Hall, 178 Victoria St, Toronto, Ontario, Canada, and online through a web-based platform, on May 12, 2026. The results of the vote are set out below:
Name of NomineeVotes ForVotes AgainstScott B. Bonham1,015,339,641 99.73% 2,723,661 0.27% Shelley G. Broader1,017,290,216 99.92% 773,087 0.08% Christie J.B. Clark999,717,774 98.20% 18,345,528 1.80% Daniel Debow1,016,068,995 99.80% 1,994,308 0.20% William A. Downe991,665,508 97.41% 26,397,795 2.59% Janice Fukakusa1,012,779,028 99.48% 5,284,275 0.52% M. Marianne Harris1,015,285,319 99.73% 2,776,783 0.27% Kevin Holt1,017,188,239 99.91% 875,064 0.09% Claudia Kotchka1,015,245,868 99.72% 2,817,434 0.28% Rima Qureshi1,017,188,006 99.91% 875,297 0.09% Sarah Raiss1,014,842,307 99.68% 3,220,995 0.32% Galen G. Weston996,740,679 97.91% 21,322,622 2.09% Cornell Wright1,008,044,516 99.02% 10,018,786 0.98% About Loblaw Companies Limited
Loblaw is Canada's food and pharmacy leader, and the nation's largest retailer. Loblaw provides Canadians with grocery, pharmacy and health services, other health and beauty products, apparel, general merchandise, financial services and wireless mobile products and services. With more than 2,800 locations, Loblaw, its franchisees and Associate-owners employ more than 220,000 full- and part-time employees, making it one of Canada's largest private sector employers.
Loblaw's purpose – Live Life Well® – puts first the needs and well-being of Canadians who make one billion transactions annually in the company's stores. Loblaw is positioned to meet and exceed those needs in many ways: convenient locations; more than 1,100 grocery stores that span the value spectrum from discount to specialty; full-service pharmacies at nearly 1,400 Shoppers Drug Mart® and Pharmaprix® locations and in close to 500 grocery stores; PC Financial® services; affordable Joe Fresh® fashion and family apparel; and four of Canada's top-consumer brands in Life Brand®, Farmer’s Market™, no name® and President's Choice®. For more information, visit Loblaw's website at www.loblaw.ca and Loblaw's issuer profile at www.sedarplus.ca.
For more information contact: Roy MacDonald, Vice President, Investor Relations, [email protected].
BRAMPTON, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- Being an Insider is all about the thrill of discovery, that can’t-wait-to-see-what’s-next energy. Here at President’s Choice, we’re always pushing new taste possibilities. The goal? Make this your most delicious summer yet.
“Summer starts now, and this year, we didn’t hold back,” says Mary MacIsaac, EVP & Chief Marketing Officer at Loblaw Companies Limited. “The PC® Summer Insiders Report™ is our most exciting collection yet, packed with bold new tastes that have been thoughtfully inspired, endlessly tested, and taken even further. One idea sparked another, and before we knew it, we had something truly special: the ultimate taste of summer.”
“We’re always after the next great bite," adds MacIsaac. “From products that took years to perfect, like our PC® Jerk Chicken Burger to hand-selected, fresh ingredients sourced and grown to our exacting PC® standards, every detail matters."
Speaking of not holding back, we had so many amazing PC® Must Tries, we couldn’t decide which was most worthy of the coveted front cover status… so we didn’t choose just one. For the first time in Insiders history, President’s Choice is unveiling four front covers. Team Burger or Team Sausage? Dessert or Fresh Fruit? Collect them all and let the friendly debates begin. No matter which side you pick, there’s one undeniable truth: summer belongs to Insiders.
More Memories
Turn everyday moments into unforgettable summer memories
Put something new on the 'cue with the PC® Sizzle Wheel Shrimp. Choose from Chili Crisp with tingly Szechuan pepper extract or go classic with Garlic & Herb. Slide onto the grill, sizzle, and serve straight from the tray for summer's can’t-miss stunner.Make peak-summer produce an everyday occasion with PC® greenhouse-grown tomatoes. Many of our tomatoes are grown in Leamington, ON—home to North America’s largest concentration of greenhouses—where they’re cultivated for exceptional flavour, all year round. Taste Escapes
Travel through taste with PC® flavour forays and gear that bring the escape to you.
PC® World of Flavour Chips celebrate Canada's most iconic tastes, from east to west. Crunch into Spicy Caesar, Peameal Bacon, Poutine, and Halifax’s Donair. Made with all-Canadian potatoes, these chips are a delightful reminder that there’s truly no taste like home.PC® Perfectly Portable Tabletop Grill - Full-size grill performance packed into a grill that moves with you. Complete with a prep tray and a lid that doubles as a food-grade bamboo cutting board. No matter where you go, make the destination delicious. Balanced Bliss
Wellness wins that taste as good as they feel, and flavours that spark joy, not second thoughts.
PC® Scoop Shop Ice Creams channel old-school ice cream parlour energy without artificial flavours or synthetic colours. Crafted with 100% Canadian dairy, raise a cone to the latest flavours: Rainbow Trail, Cookie Dough, and Pina Colada.Whether it’s soda without the sugar or fizz you can feel good about, PC® is all about pushing the bubble further. Meet PC® Blue Menu Passionfruit Guava Flavoured Sparkling Water: tangy, tropical, and a fresh twist on sparkling sips. Discover the full PC® Summer Insiders Report™, featuring new product innovation, recipes and fresh ideas—plus an immersive, scroll-stopping experience on the PC Optimum™ App and banner sites that bring it all to life. Products are also available at participating stores, including Real Canadian Superstore, No Frills, Maxi, Your Independent Grocer, Real Atlantic Superstore, Loblaws, Zehrs, Fortinos, Provigo, valu-mart, Dominion Stores in Newfoundland and Labrador and Shoppers Drug Mart/Pharmaprix.
PC Optimum® members can unlock even more value all summer long with exclusive offers and rewards on featured PC® products.
About Loblaw Companies Limited
Loblaw is Canada’s food and pharmacy leader, and the nation’s largest retailer. Loblaw provides Canadians with grocery, pharmacy, and healthcare services, other health and beauty products, apparel, general merchandise, financial services and wireless mobile products and services. With more than 2,800 locations, Loblaw, its franchisees and Associate-owners employ more than 220,000 full- and part-time employees, making it one of Canada’s largest private sector employers.
Loblaw’s purpose – Live Life Well® – puts first the needs and well-being of Canadians who make one billion transactions annually in the company’s stores. Loblaw is positioned to meet and exceed those needs in many ways: convenient locations; more than 1,100 grocery stores that span the value spectrum from discount to specialty; full-service pharmacies at nearly 1,400 Shoppers Drug Mart® and Pharmaprix® locations and in close to 500 grocery stores; PC Financial® services; Joe Fresh® fashion and family apparel; and four of Canada’s top-consumer brands in Life Brand®, Farmer’s Market™, no name® and President's Choice®. For more information, visit Loblaw’s website at www.loblaw.ca and Loblaw's issuer profile at www.sedarplus.ca.
A video accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/cf32ae23-3969-4dfd-8149-a7d44c38252c
President’s Choice unveils its annual PC® Summer Insiders Report™ Being an Insider is all about the thrill of discovery, that can’t-wait-to-see-what’s-next energy. He...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) as a monotherapy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and who are not candidates for PD-1 or PD-L1 inhibitor therapy. The European Commission decision on the additional Trodelvy indication is anticipated later in 2026.
Metastatic TNBC is an aggressive form of breast cancer that is associated with low survival rates. For many patients with metastatic TNBC, first-line therapy may be their only line of treatment, necessitating an urgency to act using the most effective treatment options first to maximize patient outcomes.
“Metastatic TNBC remains one of the most challenging breast cancer subtypes to treat, particularly at the time of first diagnosis of advanced disease, when therapeutic options are limited for many patients,” said Dr. Javier Cortes, Head of the International Breast Cancer Center, Madrid and Barcelona, Spain. “The CHMP’s positive opinion for sacituzumab govitecan represents an important step towards potential approval in this setting and reflects the clinically meaningful results observed in the ASCENT-03 study. Advancing effective treatment options earlier in the disease course is critical to improving outcomes for people living with metastatic TNBC.”
The CHMP’s recommendation is based on data from the Phase 3 ASCENT-03 study which demonstrated a highly statistically significant and clinically meaningful progression-free survival of Trodelvy compared to standard of care chemotherapy as a first-line treatment. In ASCENT-03, Trodelvy demonstrated a 38% reduced risk of disease progression or death in patients who are not candidates for PD-1/PD-L1 inhibitors. Gilead has also submitted an application to the U.S. Food and Drug Administration for approval of Trodelvy in this indication based on the ASCENT-03 study.
“This CHMP positive opinion for Trodelvy represents a pivotal moment for people with metastatic TNBC across Europe, and we look forward to hearing from the European Medicines Agency,” said Mika Kakefuda Derynck, MD, Senior Vice President, Clinical Development, Oncology at Gilead Sciences. “Building on the extensive clinical experience with Trodelvy in later lines of therapy, this recommendation has the potential to fundamentally change how we approach treating certain first-line metastatic TNBC patients, offering a much-needed option earlier in care when it can make the greatest difference. Each step forward means more options and more chances to change the story for people living this cancer.”
Gilead has also submitted supplemental filings to the European Medicines Agency and the U.S. Food and Drug Administration for Trodelvy in combination with Keytruda® (pembrolizumab) for patients with PD-L1 positive unresectable locally advanced or metastatic TNBC, based on data from the Phase 3 ASCENT-04 study. These applications are currently under review. If approved, Trodelvy has the potential to be a backbone treatment in 1L mTNBC, across PD-L1 status.
Trodelvy is currently approved as a second-line plus treatment for metastatic TNBC and for patients with pre-treated HR+/HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) metastatic breast cancer. Healthcare professionals have substantial clinical experience with Trodelvy, with more than 75,000 breast cancer patients treated across 60+ countries since 2020. It remains the only Trop-2-directed ADC to demonstrate meaningful overall survival benefits in both second-line or later metastatic TNBC and pre-treated HR+/HER2- metastatic breast cancer. It is also the only ADC with four positive Phase 3 trials in HER2-negative metastatic breast cancer (mBC).
The use of Trodelvy plus pembrolizumab in patients with first-line PD-L1+ metastatic TNBC and Trodelvy as monotherapy in patients with first-line metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitors are investigational, and the safety and efficacy of these uses have not been established.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
About Triple-Negative Breast Cancer
TNBC is the most aggressive type of breast cancer and has historically been difficult to treat, accounting for approximately 15% of all breast cancers. TNBC disproportionally impacts younger, premenopausal, and Black and Hispanic women. TNBC cells do not have estrogen and progesterone receptors and have limited HER2 expression. Due to the nature of TNBC, treatment options are extremely limited compared with other breast cancer types. TNBC has a higher chance of recurrence and metastases than other breast cancer types. The average time to metastatic recurrence for TNBC is approximately 2.6 years compared with 5 years for other breast cancers, and the relative five-year survival rate is much lower. Among women with metastatic TNBC, the five-year survival rate is 12%, compared with 28% for those with other types of mBC.
About Trodelvy
Trodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2-directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast and lung cancers. Trodelvy is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload. This unique combination delivers potent activity to both Trop-2 expressing cells and the tumor microenvironment through a bystander effect.
Trodelvy is currently approved in more than 60 countries for second-line or later metastatic triple-negative breast cancer (TNBC) and in more than 50 countries for certain patients with pre-treated HR+/HER2- metastatic breast cancer (mBC). Outside of Europe, Gilead has submitted supplemental applications to the U.S. Food and Drug Administration (FDA) for approval of Trodelvy based on the ASCENT-03 and ASCENT-04 studies.
Trodelvy is currently being evaluated in multiple ongoing Phase 3 trials across a range of tumor types with high Trop-2 expression. These studies with Trodelvy, both in monotherapy and in combination with pembrolizumab, involve earlier lines of treatment for TNBC and HR+/HER2- breast cancer—including in curative settings—as well as in lung and gynecologic cancers, where previous proof-of-concept studies have demonstrated clinical activity.
U.S. INDICATIONS FOR TRODELVY
TRODELVY® (sacituzumab govitecan-hziy) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with:
Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. U.S. IMPORTANT SAFETY INFORMATION FOR TRODELVY
BOXED WARNING: NEUTROPENIA AND DIARRHEA
TRODELVY can cause severe, life-threatening, or fatal neutropenia. Withhold TRODELVY for absolute neutrophil count below 1500/mm3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Primary prophylaxis with G-CSF is recommended for all patients at increased risk of febrile neutropenia. Initiate anti-infective treatment in patients with febrile neutropenia without delay. TRODELVY can cause severe diarrhea. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold TRODELVY until resolved to ≤ Grade 1 and reduce subsequent doses. CONTRAINDICATIONS
Severe hypersensitivity reaction to TRODELVY. WARNINGS AND PRECAUTIONS
Neutropenia: Severe, life-threatening, or fatal neutropenia can occur as early as the first cycle of treatment and may require dose modification. Neutropenia occurred in 64% of patients treated with TRODELVY. Grade 3-4 neutropenia occurred in 49% of patients. Febrile neutropenia occurred in 6%. Neutropenic colitis occurred in 1.4%. Primary prophylaxis with G-CSF is recommended starting in the first cycle of treatment in all patients at increased risk of febrile neutropenia, including older patients, patients with previous neutropenia, poor performance status, organ dysfunction, or multiple comorbidities. Monitor absolute neutrophil count (ANC) during treatment. Withhold TRODELVY for ANC below 1500/mm3 on Day 1 of any cycle or below 1000/mm3 on Day 8 of any cycle. Withhold TRODELVY for neutropenic fever. Treat neutropenia with G-CSF and administer prophylaxis in subsequent cycles as clinically indicated or indicated in Table 2 of USPI.
Diarrhea: Diarrhea occurred in 64% of all patients treated with TRODELVY. Grade 3-4 diarrhea occurred in 11% of patients. One patient had intestinal perforation following diarrhea. Diarrhea that led to dehydration and subsequent acute kidney injury occurred in 0.7% of all patients. Withhold TRODELVY for Grade 3-4 diarrhea and resume when resolved to ≤ Grade 1. At onset, evaluate for infectious causes and if negative, promptly initiate loperamide, 4 mg initially followed by 2 mg with every episode of diarrhea for a maximum of 16 mg daily. Discontinue loperamide 12 hours after diarrhea resolves. Additional supportive measures (e.g., fluid and electrolyte substitution) may also be employed as clinically indicated. Patients who exhibit an excessive cholinergic response to treatment can receive appropriate premedication (e.g., atropine) for subsequent treatments.
Hypersensitivity and Infusion-Related Reactions: TRODELVY can cause serious hypersensitivity reactions including life-threatening anaphylactic reactions. Severe signs and symptoms included cardiac arrest, hypotension, wheezing, angioedema, swelling, pneumonitis, and skin reactions. Hypersensitivity reactions within 24 hours of dosing occurred in 35% of patients. Grade 3-4 hypersensitivity occurred in 2% of patients. The incidence of hypersensitivity reactions leading to permanent discontinuation of TRODELVY was 0.2%. The incidence of anaphylactic reactions was 0.2%. Pre-infusion medication is recommended. Have medications and emergency equipment to treat such reactions available for immediate use. Observe patients closely for hypersensitivity and infusion-related reactions during each infusion and for at least 30 minutes after completion of each infusion. Permanently discontinue TRODELVY for Grade 4 infusion-related reactions.
Nausea and Vomiting: TRODELVY is emetogenic and can cause severe nausea and vomiting. Nausea occurred in 64% of all patients treated with TRODELVY and Grade 3-4 nausea occurred in 3% of these patients. Vomiting occurred in 35% of patients and Grade 3-4 vomiting occurred in 2% of these patients. Premedicate with a two or three drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor antagonist or an NK1 receptor antagonist as well as other drugs as indicated) for prevention of chemotherapy-induced nausea and vomiting (CINV). Withhold TRODELVY doses for Grade 3 nausea or Grade 3-4 vomiting and resume with additional supportive measures when resolved to Grade ≤ 1. Additional antiemetics and other supportive measures may also be employed as clinically indicated. All patients should be given take-home medications with clear instructions for prevention and treatment of nausea and vomiting.
Increased Risk of Adverse Reactions in Patients with Reduced UGT1A1 Activity: Patients homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia and may be at increased risk for other adverse reactions with TRODELVY. The incidence of Grade 3-4 neutropenia was 58% in patients homozygous for the UGT1A1*28, 49% in patients heterozygous for the UGT1A1*28 allele, and 43% in patients homozygous for the wild-type allele. The incidence of Grade 3-4 anemia was 21% in patients homozygous for the UGT1A1*28 allele, 10% in patients heterozygous for the UGT1A1*28 allele, and 9% in patients homozygous for the wild-type allele. Closely monitor patients with known reduced UGT1A1 activity for adverse reactions. Withhold or permanently discontinue TRODELVY based on clinical assessment of the onset, duration and severity of the observed adverse reactions in patients with evidence of acute early-onset or unusually severe adverse reactions, which may indicate reduced UGT1A1 function.
Embryo-Fetal Toxicity: Based on its mechanism of action, TRODELVY can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TRODELVY and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TRODELVY and for 3 months after the last dose.
ADVERSE REACTIONS
In the pooled safety population, the most common (≥ 25%) adverse reactions including laboratory abnormalities were decreased leukocyte count (84%), decreased neutrophil count (75%), decreased hemoglobin (69%), diarrhea (64%), nausea (64%), decreased lymphocyte count (63%), fatigue (51%), alopecia (45%), constipation (37%), increased glucose (37%), decreased albumin (35%), vomiting (35%), decreased appetite (30%), decreased creatinine clearance (28%), increased alkaline phosphatase (28%), decreased magnesium (27%), decreased potassium (26%), and decreased sodium (26%).
In the ASCENT study (locally advanced or metastatic triple-negative breast cancer), the most common adverse reactions (incidence ≥25%) were fatigue, diarrhea, nausea, alopecia, constipation, vomiting, abdominal pain, and decreased appetite. The most frequent serious adverse reactions (SAR) (>1%) were neutropenia (7%), diarrhea (4%), and pneumonia (3%). SAR were reported in 27% of patients, and 5% discontinued therapy due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the ASCENT study were reduced neutrophils, leukocytes, and lymphocytes.
In the TROPiCS-02 study (locally advanced or metastatic HR-positive, HER2-negative breast cancer), the most common adverse reactions (incidence ≥25%) were diarrhea, fatigue, nausea, alopecia, and constipation. The most frequent serious adverse reactions (SAR) (>1%) were diarrhea (5%), febrile neutropenia (4%), neutropenia (3%), abdominal pain, colitis, neutropenic colitis, pneumonia, and vomiting (each 2%). SAR were reported in 28% of patients, and 6% discontinued therapy due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the TROPiCS-02 study were reduced neutrophils and leukocytes.
DRUG INTERACTIONS
UGT1A1 Inhibitors: Concomitant administration of TRODELVY with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38. Avoid administering UGT1A1 inhibitors with TRODELVY.
UGT1A1 Inducers: Exposure to SN-38 may be reduced in patients concomitantly receiving UGT1A1 enzyme inducers. Avoid administering UGT1A1 inducers with TRODELVY.
Please see full Prescribing Information, including BOXED WARNING.
About Gilead and Kite Oncology
Gilead and Kite Oncology are working to transform how cancer is treated. We are innovating with next-generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody-drug conjugate technologies and small molecules to cell therapy-based approaches, we are creating new possibilities for people with cancer.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress or complete clinical trials or studies within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing and additional clinical trials or studies, including those involving Trodelvy; uncertainties relating to regulatory applications and related filing and approval timelines, including such as the pending applications for Trodelvy in 1L mTNBC and potential applications for programs and/or indications currently under evaluation, and the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; the possibility that Gilead may make a strategic decision to discontinue development of these programs and, as a result, these programs may never be successfully commercialized for the indications currently under evaluation; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.
Trodelvy, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.
U.S. Prescribing Information for Trodelvy, including BOXED WARNING, is available at www.gilead.com.
For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).
May 26, 2026 07:00 ET | Source: Loblaw Companies Limited
TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- Ahead of Menstrual Health Day on May 28, Shoppers Foundation for Women’s Health™ is proud to announce $300,000 in funding commitments over two years to support organizations advancing menstrual equity in Canada.
Nearly one in six Canadians has struggled to access the menstrual products they need1. Since 2022, Shoppers Foundation for Women’s Health™ has donated more than $2.3M to 24 community organizations across Canada to help improve access to essential menstrual products for those who need them most.
The Foundation is building on this impact with its latest funding commitment, that will provide $150,000 over two years to both Moon Time Connections (MTC), Canada’s only national Indigenous-led menstrual equity organization, and Help a Girl Out (HAGO), a registered charity focused on menstrual and uterine health education and access.
“Menstrual equity is about more than access to products, it’s about dignity, education, health, and ensuring people can fully participate in school, work and everyday life,” says Paulette Minard, Director of Community Investment and Shoppers Foundation for Women’s Health™. “Through partnerships with organizations like Moon Time Connections and Help a Girl Out, we’re expanding access to education, community support, and essential menstrual care for people across Canada.”
Moon Time Connections supports northern and remote First Nations, Inuit and Métis (FNIM) menstruators through access to products, menstrual health education and culturally grounded programming in remote and northern communities.
“Shoppers Foundation for Women’s Health™ was the first major funder of Moon Time Connections. From funding our first research project to supporting the growth of our team, the Foundation’s support has been invaluable and its impact profound,” says Nicole White, Founder, Moon Time Connections.
Help a Girl Out works to advance menstrual equity through product access, menstrual and uterine health education, and empowerment opportunities for women, girls and people who menstruate.
“HAGO’s number one priority is building programs that are informed by and tailored to the needs of individuals experiencing period poverty or lacking access to adequate menstrual and uterine health education,” explains Yanique Brandford, Executive Director, Help a Girl Out. “This partnership with Shoppers Foundation for Women’s Health™ will help strengthen and expand community-informed programs that provide meaningful, tangible and culturally responsive resources to individuals impacted by menstrual inequity.”
Canadians are invited to join Shoppers Foundation for Women’s Health™ in expanding access to menstrual products through the annual Pad It Forward donation campaign. From May 23 to June 19, customers can donate period products at Shoppers Drug Mart® and Pharmaprix® stores nationwide, with all products collected directly supporting local community organizations.
About Shoppers Foundation for Women’s Health™
Shoppers Foundation for Women’s Health™ – the charitable arm of Shoppers Drug Mart® – is committed to helping Canadian women lead healthier lives, by making care more equitable and accessible. In 2022, the Foundation set an ambitious goal: to contribute $50M by 2026 towards women’s health initiatives that are making care more equitable and accessible. This milestone has been surpassed, ahead of schedule, and Shoppers Foundation remains steadfast in its commitment to build a future in which more women in Canada can lead healthier lives." Learn more at shoppersfoundation.ca.
About Shoppers Drug Mart Inc.
Shoppers Drug Mart Inc. is one of the most recognized and trusted names in Canadian retailing. The company is the licensor of full-service retail drug stores operating under the name Shoppers Drug Mart® (Pharmaprix® in Québec). With more than 1,350 Shoppers Drug Mart® and Pharmaprix® stores operating in prime locations in each province and two territories, the company is one of the most convenient retailers in Canada. The company also licenses or owns more than 150 medical clinic pharmacies operating under the name Shoppers Simply Pharmacy® (Pharmaprix Simplement Santé® in Québec). In addition to its retail store network, the company owns Shoppers Drug Mart Specialty Health Network Inc., a provider of specialty drug distribution, pharmacy and comprehensive patient support services, MediSystem Inc., a provider of pharmaceutical products and services to long-term care facilities and Lifemark Health Group, Canada’s leading provider of outpatient physiotherapy, massage therapy, occupational therapy, chiropractic, mental health, and other ancillary rehabilitation services. Shoppers Drug Mart® is an independent operating division of Loblaw Companies Limited.
1 Women and Gender Equality Canada, Menstrual equity, Government of Canada, accessed May 2026. https://www.canada.ca/en/women-gender-equality/funding/equality-action/menstrual-equity.html
TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- In the latest edition of its Food Inflation Report, Loblaw is pleased to provide context around what’s impacting food prices – now and into the future. This report follows Statistics Canada’s release of data for the month of April.
According to StatsCan, overall inflation rose to 2.8% YoY in April, up from 2.4% in March, while food purchased from stores increased 3.8% YoY after a 4.4% increase the month prior. StatsCan noted that a sharp rise in gasoline prices tied to conflict in the Middle East, alongside seasonal fuel market dynamics, contributed to the outcome.
The Loblaw Food Inflation Report includes context surrounding seasonal produce, energy markets, fertilizer expenses, trade discussions, and more.
CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- Real Canadian Superstore, Tsuut'ina Nation and Taza Development Corp. are marking the next phase of the new Superstore at Buffalo Run with a planned fall 2026 opening, with construction well underway.
The new Real Canadian Superstore at Buffalo Run will be the first Superstore in Alberta developed in collaboration with an Indigenous community. As a major retail presence within the growing Buffalo Run community, the store represents an important step in bringing everyday amenities, new employment opportunities and long-term economic benefits to the Tsuut'ina and Calgary regions.
“This development represents far more than a grocery store. It is another meaningful milestone in Taza's vision to bring convenient, high-quality amenities to the region while supporting sustained, long-term economic growth for Tsuut'ina Nation. We are proud to see this partnership continue to take shape and look forward to the store opening later this fall.”
— James Robertson, President of Taza Development Corp.
With opening preparations now advancing, a hiring event for the new location will take place on Wednesday, August 26. The store will also create opportunities to continue building relationships with local and Indigenous vendors, while supporting Superstore's broader commitment to Indigenous allyship and community partnership.
“At the heart of our business are people, purpose and passion. We are excited to bring meaningful employment opportunities to Buffalo Run, deepen relationships with Indigenous vendors and continue building on our longstanding allyship work across Canada. This store is part of something bigger, and we look forward to opening our doors to the community.”
— Jonathan Carroll, Senior Vice President of Operations for Superstore
Additional details about the hiring event, store experience, vendor partnerships and grand opening plans will be shared closer to opening.
For media inquiries, contact:
Maureen Henderson
Vice President, Community Experience
Taza Development Corporation [email protected] | 403-992-8388
About Loblaw Companies Limited
Loblaw is Canada’s food and pharmacy leader, and the nation’s largest retailer. Loblaw provides Canadians with grocery, pharmacy, and healthcare services, other health and beauty products, apparel, general merchandise, financial services and wireless mobile products and services. With more than 2,800 locations, Loblaw, its franchisees and Associate-owners employ more than 220,000 full- and part-time employees, making it one of Canada’s largest private sector employers.
Loblaw’s purpose – Live Life Well® – puts first the needs and well-being of Canadians who make one billion transactions annually in the company’s stores. Loblaw is positioned to meet and exceed those needs in many ways: convenient locations; more than 1,100 grocery stores that span the value spectrum from discount to specialty; full-service pharmacies at nearly 1,400 Shoppers Drug Mart® and Pharmaprix® locations and in close to 500 grocery stores; PC Financial® services; Joe Fresh® fashion and family apparel; and four of Canada’s top-consumer brands in Life Brand®, Farmer’s Market™, no name® and President's Choice®. For more information, visit Loblaw’s website at www.loblaw.ca and Loblaw's issuer profile at www.sedarplus.ca.
About Taza
Decades in the making, Taza is one of the largest and most influential First Nation development projects located on 1,200 acres of Tsuut’ina land. Consisting of three unique, but related community villages—Taza Park, Buffalo Run and The Crossing, Taza is integrated through a comprehensive framework of Tsuut’ina and City of Calgary infrastructure. The villages are physically connected via Tsuut’ina Trail, which is part of the Southwest Calgary Ring Road, a critical piece of transportation infrastructure for the Calgary and Southern Alberta regions. Each community village has a distinct character built around a guiding philosophy and distinct design principles. Led by Taza Development Corp, Taza will create a unique sense of place, drawing on the history, culture and stories of the Tsuut’ina Nation.
About Taza Development Corp.
Taza Development Corp. (TDC) is a wholly owned subsidiary of Canderel and serves as the development entity for Taza, a 50/50 partnership between the Tsuut’ina Nation and Canderel, a leading Canadian real estate company. Adjacent to the southwest quadrant of Calgary, Alberta, the Tsuut’ina Nation is home to approximately 2,400 community members. Guided by a Board of Directors, TDC is advancing the long-term development of Taza’s three distinct yet interconnected villages—Taza Park, Buffalo Run, and The Crossing—across 1,200 acres over the next 25+ years. This transformational project is designed to drive meaningful social and economic prosperity for the Tsuut’ina Nation and the broader region.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8e6779a1-1624-441f-8784-e7d7ce886420
Buffalo Run Real Canadian Superstore Rendering Buffalo Run Real Canadian Superstore slated to open Fall 2026
